Who Paid My Doc
Daniel Peterson
Neurological Surgery Austin, TX Medical Doctor
NPI 1518027366 CMS profile 249516
3003 Bee Caves Rd Ste 201, Austin, TX 78746
General payments
$442,287
Research payments
$22,609
Ownership & investment interest
$34,339,156
Research they led as principal investigator
$94,634
Through program year 2025, Daniel Peterson of Austin, TX is reported in the CMS Open Payments database as having received $442,287 across 905 general payments and $22,609 in research payments paid to them. Separately, studies naming them as principal investigator received $94,634 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $34,339,156 across 21 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
16 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $130,425 | 123 | |
| 2024 | General | $131,245 | 134 | |
| 2023 | General | $125,879 | 115 | |
| 2023 | Research | $16,752 | 7 | |
| 2022 | General | $42,429 | 139 | |
| 2022 | Research | $5,857 | 2 | |
| 2021 | General | $5,393 | 104 | |
| 2020 | General | $1,497 | 73 | |
| 2019 | General | $5,419 | 217 | |
| 2025 | Ownership | $5,266,281 | 3 | |
| 2024 | Ownership | $5,266,281 | 3 | |
| 2023 | Ownership | $5,266,281 | 3 | |
| 2022 | Ownership | $4,527,986 | 3 | |
| 2021 | Ownership | $4,527,986 | 3 | |
| 2020 | Ownership | $4,527,986 | 3 | |
| 2019 | Ownership | $4,956,355 | 3 |
Beside peers
- Daniel Peterson
- Neurological Surgery median
- Middle half of Neurological Surgery
- National median
In program year 2025, general payments to Daniel Peterson were reported at $130,425. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.
Show as a table
| Year | Daniel Peterson | Neurological Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,419 | $582 | $138–$3,006 | $163 |
| 2020 | $1,497 | $294 | $76–$2,174 | $114 |
| 2021 | $5,393 | $387 | $105–$2,432 | $132 |
| 2022 | $42,429 | $542 | $139–$2,989 | $149 |
| 2023 | $125,879 | $534 | $145–$2,697 | $160 |
| 2024 | $131,245 | $574 | $155–$3,046 | $164 |
| 2025 | $130,425 | $596 | $159–$3,102 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
677
Drug cost
$13,429
Branded share of claims
46.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Movantik Naloxegol Oxalate | Brand | 21 | $8,501 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 242 | $2,304 | |
| Methocarbamol | Generic | 190 | $900 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 54 | $690 | |
| Gabapentin | Generic | 52 | $507 | |
| Meloxicam | Generic | 30 | $186 | |
| Tramadol Hcl | Generic | 50 | $137 | |
| Methylprednisolone | Generic | 25 | $103 | |
| Pregabalin | Generic | 13 | $103 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 55 billing codesPaid by Medicare
$179,806
Medicare patients
311
Services billed
871
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 73% | |
| Ischemic heart disease | 29% | |
| Depression | 26% | |
| Diabetes | 23% | |
| Atrial fibrillation | 16% | |
| Chronic kidney disease | 16% | |
| Cancer | 14% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
914 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurological Surgery in Texas
Koijan Kainth
Neurological Surgery · The Woodlands, TX
Luis Duarte
Neurological Surgery · San Angelo, TX
Douglas Fox
Neurological Surgery · Austin, TX
Richard Meyrat
Neurological Surgery · Dallas, TX
Adam Lewis
Neurological Surgery · Corpus Christi, TX
Arnold Vardiman
Neurological Surgery · San Antonio, TX
Related records
Neurological Surgery in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Neurological Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.